Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Inebilizumab · Uplizna, MEDI-551

Monoclonal antibody · Kills target cells, directed at CD19 · developed by Viela Bio

Approved FDA, Jun 2020
1 Registered trials

What is Inebilizumab?

Inebilizumab-cdon (UPLIZNA) is a CD19-directed cytolytic antibody that binds CD19 on B lymphocytes and mediates antibody-dependent cellular cytolysis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Uplizna, MEDI-551, UPLIZNA
Drug type
Monoclonal antibody
Targets
CD19, aquaporin-4 (AQP4) (biomarker)
Mechanism
Kills target cells, directed at CD19
Pathways
antibody-dependent cellular cytolysis
Therapy area
Immunology, Neurology
Developer
Viela Bio
In trials of
AMGN
FDA status
Approved as Uplizna (June 11, 2020), BLA761142 · FDA label
UNII
74T7185BMM

✅ FDA-approved uses

From the indications section of the FDA label (version of Feb 8, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06590051 N/A Approved for marketing AMGN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Other drugs acting on CD19

Blinatumomab FDA approved Loncastuximab tesirine FDA approved Budoprutug Phase 1/2 MK-1045 Phase 2/3

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.